LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification Section 1, Identification Material Cefixime for Oral Suspension USP, 100 mg/5 mL Cefixime for Oral Suspension USP, 200 mg/5 mL Manufacturer Lupin Limited Mandideep 462 046 INDIA. Distributor Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 **United States** Tel. 001-410-576-2000 Fax. 001-410-576-2221 Section 2: Hazard(s) Identification Section 2, Hazard(s) identification **Fire and Explosion** Expected to be non-combustible.

| Health | Cefixime for oral suspension is contraindicated in patients with |
|--------|--|
| | known allergy to cefixime or other cephalosporins. |

Environment No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

Ingredients

CAS

Cefixime (as trihydrate)

79350-37-1

| Section 4: First-Aid Measures | | | | |
|-----------------------------------|---|--|--|--|
| Section 4, First-aid measures | | | | |
| Ingestion | If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention. | | | |
| Inhalation | Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance. | | | |
| Skin Contact | Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs. | | | |
| Eye Contact | Flush eyes with plenty of water. Get medical attention. | | | |
| NOTES TO HEALTH PROFESSIONALS | | | | |
| Medical Treatment | Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. | | | |
| OVERDOSAGE | Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of cefixime did not differ from the profile seen in patients treated at the recommended doses. | | | |
| Section 5: Fire-Fighting Measures | | | | |
| Section 5, Fire-fighting measures | | | | |
| Fire and Explosion Hazards | Assume that this product is capable of sustaining combustion. | | | |
| Extinguishing Media | Water spray, carbon dioxide, dry chemical powder or appropriate foam. | | | |
| Special Firefighting Procedures | For single units (packages): No special requirements needed. | | | |
| | For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters. | | | |
| Hazardous Combustion Products | Hazardous combustion or decomposition products are expected when the product is exposed to fire. | | | |

Section 6: Accidental Release Measures Section 6, Accidental release measures Wear protective clothing and equipment consistent with the degree of hazard. Environmental Precautions For large spills, take precautions to prevent entry into waterways sewers, or surface drainage systems. Clean-up Methods Collect and place it in a suitable, properly labeled container for recovery or disposal.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling

Storage

No special control measures required for the normal handling of this product.

Prior to reconstitution: Store drug powder at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature].

After reconstitution: Store at room temperature or under refrigeration.

Keep tightly closed.

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical FormCefixime for Oral Suspension USP, 100 mg/5 mL is an off-white to pale yellow
colored powder. After reconstituted as directed, each 5 mL of reconstituted
suspension contains 100 mg of cefixime as the trihydrate and is supplied as
follows:

NDC 68180-405-01 - 50 mL Bottle

Cefixime for Oral Suspension USP, 200 mg/5 mL is an off-white to pale yellow colored powder. After reconstituted as directed, each 5 mL of reconstituted suspension contains 200 mg of cefixime as the trihydrate and is supplied as follows:

NDC 68180-407-03 - 50 mL Bottle

NDC 68180-407-04 - 75 mL Bottle

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Lifetime studies in animals to evaluate carcinogenic potential have not been conducted. Cefixime did not cause point mutations in bacteria or mammalian cells, DNA damage, or chromosome damage *in vitro* and did not exhibit clastogenic potential *in vivo* in the mouse micronucleus test. In rats, fertility and reproductive performance were not affected by cefixime at doses up to 25 times the adult therapeutic dose.

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

| IATA Proper shipping Name IATA UN/ID No IATA Hazard Class IATA Packaging Group IATA Label | : | N/A N/A N/A N/A |
|---|---|--------------------------|
| IMDG - Not Regulated IMDG Proper shipping Name IMDG UN/ID No IMDG Hazard Class IMDG Flash Point IMDG Label | | N/A N/A N/A N/A |

| DOT - Not Regulated | | |
|--------------------------|---|-----|
| DOT Proper shipping Name | : | N/A |
| DOT UN/ID No | : | N/A |
| DOT Hazard Class | : | N/A |
| DOT Flash Point | : | N/A |
| DOT Packing Group | : | N/A |
| DOT Label | : | N/A |

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.